DCM
BMY.RT

Dupont Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Dupont Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-34,400
Closed -$24K – 1821
2020
Q4 		$24K Hold
34,400
– – ﹤0.01% 1274
2020
Q3 		$77K Hold
34,400
– – ﹤0.01% 1204
2020
Q2 		$123K Sell
34,400
-23,498
-41% -$84.8K ﹤0.01% 1233
2020
Q1 		$220K Sell
57,898
-41,848
-42% -$138K 0.01% 984
2019
Q4 		$300K Buy
+99,746
New +$259K 0.01% 1071

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Dupont Capital Management's BMY.RT Position: Q1 2021 in Review

Dupont Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 34,400 shares — an estimated $24K sold.

Dupont Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $300K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Dupont Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Dupont Capital Management sold 34,400 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $24K.
  • Dupont Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Dupont Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $300K in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Dupont Capital Management's 13F filing for Q1 2021, filed 29 Apr 2021.